article thumbnail

NHSE pilot to test new models of vaccination delivery

The Pharmacist

NHS England (NHSE) is launching 12 ‘demonstrator sites’ to test ‘new and innovative’ models of vaccination delivery, it has said.

Vaccines 121
article thumbnail

Agilex Biolabs Partners with Endpoints News for Webinar on Rapid Vaccine Development in Australia

Pharma Mirror

ADELAIDE- Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on “Non-clinical and clinical pathways for rapid vaccine development in Australia”, in a webinar hosted by Endpoints News Editor Arsalan Arif.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies – OCT Webinar

Pharma Mirror

ADELAIDE, AUS, Oct 19, 2021 – (ACN Newswire) – Agilex Biolabs, the Australian regulated bioanalytical and toxicology laboratory facilities for clinical trials is presenting a new webinar entitled “Getting it right! This webinar covers these platforms in detail and the. Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D,

article thumbnail

Webinar: Demand of Respiratory Illness Vaccines Exceeds Availability

Pharmacy Times

Expert discuss access barriers for the COVID-19, respiratory syncytial virus, and influenza vaccines, and ways to facilitate uptake.

article thumbnail

Primary care sites: A new avenue for clinical research

pharmaphorum

This was, and still is being, demonstrated through the UK’s COVID-19 vaccine research successes. In this pharmaphorum webinar, conducted in partnership with National Institute for Health Research (NIHR), we will hear from experts on how and why commercial researchers should be looking hard at primary care sites.

article thumbnail

Webinar on the Medical and Legal Aspects of COVID-19

Eye on FDA

Obviously testing for COVID-19, the wearing of masks, appropriate distancing, temperature screening and there has been discussion of using antibody tests as a means to screen and categorize people and even terming a positive status as an “immunity passport” Ultimately there may be a vaccine. Photo by Morning Brew on Unsplash.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23. Checkpoint modulators are forecasted to retain the largest share of this, based on the webinar.